Oncoinvent ASA
ONCIN
Company Profile
Business description
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The product candidate, Radspherin, uses the alpha-emitting radionuclide radium-224 to directly target micrometastases post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting.
Contact
Gullhaugveien 7
Oslo0484
NORT: +47 22183305
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
Our view on oil prices after Maduro is deposed
We’ve revisited our oil price assumptions after the news from Venezuela.
stocks
Nvidia: Full steam ahead with an impressive array of announcements at CES 2026
Our view of Nvidia at the current share price.
stocks
Cheapest ASX member of our Best Idea’s list
This share is trading at the lowest price to fair value of the 14 companies on the list.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,030.70 | 8.80 | -0.10% |
| CAC 40 | 8,237.43 | 25.93 | 0.32% |
| DAX 40 | 24,892.20 | 23.51 | 0.09% |
| Dow JONES (US) | 49,462.08 | 484.90 | 0.99% |
| FTSE 100 | 10,122.73 | 118.16 | 1.18% |
| HKSE | 26,710.45 | 363.21 | 1.38% |
| NASDAQ | 23,547.17 | 151.35 | 0.65% |
| Nikkei 225 | 52,518.08 | 685.28 | 1.32% |
| NZX 50 Index | 13,675.60 | 12.02 | 0.09% |
| S&P 500 | 6,944.82 | 42.77 | 0.62% |
| S&P/ASX 200 | 8,714.60 | 8.90 | -0.10% |
| SSE Composite Index | 4,083.67 | 60.25 | 1.50% |